Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus

Keeling, Stephanie; Alabdurubalnabi, Zainab; Aviña‐Zubieta, Antonio; Barr, Susan G.; Bergeron, Louise; Bernatsky, Sasha; Bourré‐Tessier, Josiane; Clarke, Ann E.; Baril-Dionne, Alexandra; Dutz, Jan P.; Ensworth, Stephanie; Fifi‐Mah, Aurore; Fortin, Paul R.; Gladman, Dafna D.; Haaland, Derek; Hanly, John G.; Hiraki, Linda T.; Hussein, Sara; Legault, Kimberly; Levy, Deborah; Lim, Lily Siok Hoon; Matsos, Mark; McDonald, Emily G.; Medina-Rosas, Jorge; Pardi, Jordi Pardo; Peschken, Christine A.; Pineau, Christian; Pope, Janet; Rader, Tamara; Reynolds, Jen; Silverman, Earl D.; Tselios, Konstantinos; Suitner, Manon; Urowitz, Murray B.; Touma, Zahi; Vinet, Évelyne

doi:10.3899/jrheum.171459

Cited by 46 publications

(56 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Индукционная терапия проводится в течение 3-6 мес в комбинации с пульс-терапией МП и назначением пероральных ГК в дозе 0,5-1,0 мг/кг. При рефрактерном к монотерапии ГК волчаночном артрите и поражениях кожи, при отсутствии противопоказаний, рекомендуется применение метотрексата (МТ) в дозе не ниже 15 мг в неделю в комбинации с фолиевой кислотой 5 мг в неделю или азатиоприн 50-150 мг в день [13,[15][16][17][18][19][20][21][22].…”

Section: цитотоксические препаратыunclassified

“…Длительный прием ГХ обеспечивает профилактику обострений, снижение активности и риск развития кардиоваскулярных осложнений. ГХ разрешен к применению у беременных и кормящих женщин с СКВ; необходимо проведение полного офтальмологического обследования 1 раз в год в связи с риском развития ретинопатии (1:5000) [13,15,21].…”

Section: антималярийные препараты гидроксихлорохинunclassified

“…Больным СКВ для лечения мышечно-скелетных проявлений, лихорадки и умеренно выраженного серозита рекомендовано применение нестероидных противовоспалительных препаратов (НПВП) в стандартных терапевтических дозах в течение короткого времени и только у пациентов с низкой степенью вероятности развития побочных эффектов [1,2,10,13,15,21].…”

Section: нестероидные противовоспалительные препаратыunclassified

“…Мониторинг ак тивности и повреждений У всех пациентов с высокой и средней активностью СКВ для определения динамики активности заболевания и эффективности терапии рекомендовано оценивать индексы SLEDAI-2K или SELENA-SLEDAI не реже 1 раза в 3 мес [6,7,9,12,14,20]. У всех пациентов с низкой активностью или ремиссией СКВ для определения динамики активности заболевания и эффективности терапии рекомендовано оценивать индексы активности SLEDAI-2K или SELENA-SLEDAI не реже 1 раза в 6 мес [7,8,10,13,15,21]. У всех пациентов с высокой и средней активностью СКВ для установления наличия потенциально необратимых поражений различных органов рекомендовано оценивать ИП по шкале SLICC/DI не реже 1 раза в 6 мес [7,9,10,13,15,21].…”

Section: вакцинацияunclassified

“…У всех пациентов с высокой и средней активностью СКВ для установления наличия потенциально необратимых поражений различных органов рекомендовано оценивать ИП по шкале SLICC/DI не реже 1 раза в 6 мес [7,9,10,13,15,21]. У всех пациентов с низкой активностью или ремиссией СКВ для установления наличия потенциально необратимых поражений различных органов рекомендовано оценивать ИП по шкале SLICC/DI не реже 1 раза в 12 мес [1,2,7,9,10,13,15,21].…”

Section: вакцинацияunclassified

See 4 more Smart Citations

Management of patients with systemic lupus erythematosus in real clinical practice

Асеева¹,

Соловьев²,

Попкова³

et al. 2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Section: цитотоксические препаратыunclassified

Section: антималярийные препараты гидроксихлорохинunclassified

Section: нестероидные противовоспалительные препаратыunclassified

Section: вакцинацияunclassified

See 3 more Smart Citations

Management of patients with systemic lupus erythematosus in real clinical practice

Асеева¹,

Соловьев²,

Попкова³

et al. 2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review

Bartels

Jorge

Feldman

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveWe aimed to develop readily measurable digital quality measure statements for clinical care in systemic lupus erythematosus (SLE) using a multistep process guided by consensus methods.MethodsUsing a modified Delphi process, an American College of Rheumatology (ACR) workgroup of SLE experts reviewed all North American and European guidelines from 2000 to 2020 on treatment, monitoring, and phenotyping of patients with lupus. Workgroup members extracted quality constructs from guidelines, rated these by importance and feasibility, and generated evidence‐based quality measure statements. The ACR Rheumatology Informatics System for Effectiveness (RISE) Registry was queried for measurement data availability. In 3 consecutive Delphi sessions, a multidisciplinary Delphi panel voted on the importance and feasibility of each statement. Proposed measures with consensus on feasibility and importance were ranked to identify the top 3 measures.ResultsReview of guidelines and distillation of 57 quality constructs resulted in 15 quality measure statements. Among these, 5 met high consensus for importance and feasibility, including 2 on treatment and 3 on laboratory monitoring measures. The 3 highest‐ranked statements were recommended for further measure specification as SLE digital quality measures: 1) hydroxychloroquine use, 2) limiting glucocorticoid use >7.5 mg/day to <6 months, and 3) end‐organ monitoring of kidney function and urine protein excretion at least every 6 months.ConclusionThe Delphi process selected 3 quality measures for SLE care on hydroxychloroquine, glucocorticoid reduction, and kidney monitoring. Next, measures will undergo specification and validity testing in RISE and US rheumatology practices as the foundation for national implementation and use in quality improvement programs.image

show abstract

Glucocorticoid‐induced osteonecrosis in systemic lupus erythematosus patients

Kaneko

Chen

Kaufman

et al. 2021

Clinical & Translational Med

View full text Add to dashboard Cite

Osteonecrosis (ON) is a complex and multifactorial complication of systemic lupus erythematosus (SLE). ON is a devastating condition that causes severe pain and compromises the quality of life. The prevalence of ON in SLE patients is variable, ranging from 1.7% to 52%. However, the pathophysiology and risk factors for ON in patients with SLE have not yet been fully determined. Several mechanisms for SLE patients’ propensity to develop ON have been proposed. Glucocorticoid is a widely used therapeutic option for SLE patients and high‐dose glucocorticoid therapy in SLE patients is strongly associated with the development of ON. Although the hips and knees are the most commonly affected areas, it may be present at multiple anatomical locations. Clinically, ON often remains undetected until patients feel discomfort and pain at specific sites at which point the process of bone death is already advanced. However, strategies for prevention and options for treatment are limited. Here, we review the epidemiology, risk factors, diagnosis, and treatment options for glucocorticoid‐induced ON, with a specific focus on patients with SLE.

show abstract

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus

Cited by 46 publications

References 86 publications

Management of patients with systemic lupus erythematosus in real clinical practice

Management of patients with systemic lupus erythematosus in real clinical practice

Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review

Glucocorticoid‐induced osteonecrosis in systemic lupus erythematosus patients

Contact Info

Product

Resources

About